|
|
Volumn 92, Issue 23, 2000, Pages 1878-1879
|
|
Targeted cancer therapies attempt to hit the bull's-eye
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BACTERIAL TOXIN;
BACTERIUM ANTIBODY;
CISPLATIN;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
IMMUNOTOXIN;
LIPOSOME;
MONOCLONAL ANTIBODY;
PACLITAXEL;
PSEUDOMONAS EXOTOXIN;
TRASTUZUMAB;
TUMOR PROTEIN;
UNCLASSIFIED DRUG;
VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;
VIRUS VECTOR;
ADENOVIRUS;
ADULT;
APOPTOSIS;
BREAST CANCER;
CANCER CENTER;
CANCER CHEMOTHERAPY;
CANCER THERAPY;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG DELIVERY SYSTEM;
DRUG DIFFUSION;
DRUG EFFICACY;
DRUG SPECIFICITY;
DRUG TARGETING;
GENE OVEREXPRESSION;
GENETIC HETEROGENEITY;
HUMAN;
LEUKEMIA;
LYMPHOMA;
NATIONAL HEALTH SERVICE;
NOTE;
ONCOGENE NEU;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
SIDE EFFECT;
TARGET ORGAN;
TUMOR VASCULARIZATION;
UNITED STATES;
|
|
EID: 0034614110
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/92.23.1878 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|